Nonclinical Development of Biologics, Vaccines and Specialty Biologics

Edited by:   Lisa Plitnick (Merck Research Laboratories Merck and Co. Inc. West Point PA USA), Claudette LaTonya Fuller (Therapeutic Area Leader for Infectious Disease, Merck Research Laboratories in West Point, Pennsylvania, USA)
Imprint:   Academic Press Inc
Country of Publication:   United States
Edition:   2nd edition
Dimensions:   Height: 234mm,  Width: 191mm, 
Weight:   450g
ISBN:   9780443133442
ISBN 10:   0443133441
Pages:   450
Publication Date:   01 October 2024
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Forthcoming

Dr. Lisa Plitnick received a BA in Biology from The State University of New York at Oswego and an MS and a PhD in Immunology from the Albany Medical College in Albany, New York. In 2002, she joined the Department of Safety Assessment and Laboratory Animal Resources in Merck Research Laboratories where she worked as a Study Director and currently serves as the Preclinical Safety Lead on drug development teams and as the Therapeutic Area Lead for Vaccines. She is the Scientific and Regulatory Advisor for the In Vivo Biologics Release Testing Group in the Merck Manufacturing Division and the Scientific Advisor for the Immunotoxicology Laboratory. Dr. Plitnick has edited a book, contributed to several book chapters on biologics and vaccines, and peer-reviewed journal articles. She is a member of the HESI ILSI Immunotoxicology Technical Committee, the BioSafe Specialty Biologics Expert and MoA/MoT working groups, and the Merck Immunotoxicology Council. Dr. Claudette (Tonya) Fuller completed her PhD in Viral Immunology at the University of Virginia. She completed postdoctoral work at the University of Texas Medical Branch and National Cancer Institute - National Institutes of Health, focusing on molecular immunology. She currently serves as a Therapeutic Area Leader for Infectious Disease at Merck Research Laboratories in West Point, Pennsylvania, USA. As Therapeutic Area Leader, she is responsible for overseeing the nonclinical development of antibacterial and antifungal programs within the Infectious Disease Therapy Area at Merck where is she is also the co-chair of the ImmunoTox and Biologics Advisory Council that provides expert opinion to all stages of drug discovery and development programs. She is a proven leader in the nonclinical drug development in multiple therapeutic areas (Biologics, Immunology, Immuno-Oncology, Virology, and Anti-Bacterials). She enjoys building and leading diverse and inclusive nonclinical drug safety/operations teams to strategically advance the development of innovative therapeutics.